The attitudes of community-based opioid use disorder treatment center staff toward the emergency department as a site of initiation were varied, with some feeling that emergency department-initiated buprenorphine may attract patients who were not experiencing life-threatening emergencies.
The protozoan intranasal treatment was associated with a strong increase of immune cells within the lung.
Reporting vaccination data to Immunization Information Systems databases can support public health surveillance activities.
Specialty pharmacists—those caring for patients with serious, sometimes life-threatening conditions such as cancer or rheumatologic disease—are not immune from the ongoing labor crisis.
The preventive effect is believed to be a result of compounds unique to cranberries called proanthocyanidins.
The imaging agent and visualization system will be an adjunct to standard of care to reduce residual cancer in the lumpectomy cavity during initial surgery.
The FDA’s final decision is expected by a Prescription Drug User Fee Act goal date in August 2023.
Adalimumab-adbm (Cyltezo Pen; Boehringer Ingelheim) is approved by the FDA as an interchangeable biosimilar to Humira.
Death occurs from air embolism after pneumatic line was connected to an intravenous catheter.
Pharmacists should continue to monitor payer policy changes and reimbursement rates and improve understanding of electronic order entry.
The diagnosis should change from an influenza infection if the patient has gradually increasing chest pain after the original diagnosis.
In neonatal intensive care units, probiotic usage was associated with a decline in necrotizing enterocolitis, but not with sepsis or mortality rates.
Anne Cassity, JD, senior vice president of Public Affairs at the National Community Pharmacists Association discusses congressional and lawmaker trends on pharmacy benefits manager reform with guests, Adam Harbison and Kaite Krell.
The risk of long COVID-19 in females in the least deprived areas was comparable to the risk of males in the most deprived areas.
A barrier in effectively treating HIV has been the latency of infected CD4+ T cells, which are often treatment-resistant and contribute to the persistence nature of the virus.
From 2017 to 2021, Australia did not experience a large increase in infections of serotype 19A across all ethnic and age groups, unlike New Zealand.
Long-term data show that early treatment with ofatumumab decreased confirmed disability worsening in nearly all study patients with relapsing multiple sclerosis.
Avapritinib has been FDA approved for the treatment of advanced systemic mastocytosis since June 2021.
Many patients with post-COVID-19 condition reported perceived cognitive deficits early during their COVID-19 infection as well.
Beremagene geperpavec completely closed severe blistering and wounds in more than half of all patients with dystrophic epidermolysis bullosa with specific mutations.
Products include a 3-in-1 probiotic product and OTC hearing aids.
Understanding causes, consequences proves vital to develop therapies that exploit vulnerabilities of the cancer cells.
OTC nicotine replacement products can come in a transdermal patch, nicotine gum, or lozenges.
The results of a recent study suggest that a testing policy change for C. difficile could decrease the risk of additional infections and the corresponding economic burden on the hospital.
Supportive nurse managers and supervisors as well as nurses’ involvement in organizational governance may help lower hospital-onset Clostridioides difficile infection in acute care hospitals.
Findings suggest that mice derived from and breastfed by immunized mothers were capable of producing anti- pneumococcal surface protein A (PspA) specific antibodies, despite having no direct exposure to PspA.
A lack of understanding of the burden and preventability of non-ventilator-associated hospital-acquired pneumonia contribute to hospitals’ limited attention to the infection.
Treatment with epcoritamab-bysp showed a 61% overall response rate and a 38% complete response rate in heavily pretreated patients with R/R DLBCL.
The approval marks the first and only FDA-approved treatment for dry eye disease that directly targets tear evaporation.
These appointments help identify medication-related problems and serve as a platform for additional education.
